Date: 2015-06-02
Type of information: Nomination
Compound: chief development officer
Company: Anergis (Switzerland)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 2, 2015, Anergis announced the appointment
of Kim Simonsen as Chief Development Officer. Mr. Simonsen will head Anergis´ global product development from preclinical development to registration, including CMC, clinical development, regulatory affairs and global project management. Kim Simonsen joins Anergis from Ablynx where he was Chief Operations Officer. Prior to that, he was Senior Director, Global Clinical Development, at ALK Abello,
where he led the clinical development of Grazax®, the first marketed grass pollen allergy immunotherapy tablet. From 2000 to 2005, Mr. Simonsen was Chief Executive Officer of the CRO Medicon A/S after having held various clinical
development roles at big pharmaceutical companies, e.g. as Medical Director of Novartis Healthcare Director of Clinical Operations at Novo Nordisk, and as Medical Director and Clinical Expert at Sandoz.Prior to joining the biopharmaceutical industry in 1986, Mr. Simonsen trained as an MD at Copenhagen University and worked for five years at two different clinics in the Copenhagen area, focusing on internal medicine (gastroenterology, respiratory,
cardiology).
Financial terms:
Latest news:
Is general: Yes
